

Merger Between Lonza K.K. and Capsugel Japan, Inc., and Relocation of the Tokyo Office

As of September 1, 2021, Lonza K.K. and Capsugel Japan, Inc. have merged, and we operate under the name of Lonza K.K.

Going forward, this merger allows us to create more efficient management structure. As a member of Lonza Group, we will make every effort to contribute to enabling better healthcare in Asia Pacific.

We greatly appreciate the continued understanding and cooperation of all our stakeholders during the merger process.

Toru Kobayashi
General Manager
Lonza K.K.

Lonza K.K. new company details

Tokyo Head Office (New address)

9th floor, Nihonbashi Kato Building 1-14, Nihonbashi 2-chome, Chuo-ku, Tokyo

Sagamihara Office (Main store address)

4-3-36 Minamihashimoto, Chuo-ku, Sagamihara, Kanagawa

Locations and areas of business

Tokyo Head Office:

Bioscience business (Reagents and Devices for R&D and Testing)

Contract Development & Manufacturing Organization

Small Molecules

Biologics (Mammalian, Microbial, Bioconjugate,mRNA)

Cell & Gene Therapy

Sagamihara Office:

Hard Capsules related

Health ingredients

Inquiries about this external notification

Lonza K.K. Tokyo Head Office (main phone line) 03 6264 7630

contact.us.jp@lonza.com

About Lonza

Lonza is the preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. Our unparalleled breadth of offerings enables our customers to commercialize their discoveries and innovations in the healthcare sector.

Founded in 1897 in the Swiss Alps, today, Lonza operates across five continents. With approximately 15,000 employees, we comprise high-performing teams and individual talent that make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 2.5 billion with a CORE EBITDA of CHF 847 million in H1 2021. Find out more at www.lonza.com

Follow @Lonza on [LinkedIn](#)

Follow @LonzaGroup on [Twitter](#)

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this external notification may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this external notification due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this external notification.